1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-8 of 8 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancerPonnusamy, S.; Coss, C.; Thiyagarajan, T.; Watts, K.; Hwang, D.-J.; He, Y.; Selth, L.; McEwan, I.; Duke, C.; Pagadala, J.; Singh, G.; Wake, R.; Ledbetter, C.; Tilley, W.; Moldoveanu, T.; Dalton, J.; Miller, D.; Narayanan, R.
2017Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancerPaltoglou, S.; Das, R.; Townley, S.; Hickey, T.; Tarulli, G.; Coutinho, I.; Fernandes, R.; Hanson, A.; Denis, I.; Carroll, J.; Dehm, S.; Raj, G.; Plymate, S.; Tilley, W.; Selth, L.
2016Computational reconstruction of NFκB pathway interaction mechanisms during prostate cancerBörnigen, D.; Tyekucheva, S.; Wang, X.; Rider, J.R.; Lee, G.S.; Mucci, L.A.; Sweeney, C.; Huttenhower, C.; Przytycka, T.M.
2013Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancerRavindranathan, P.; Lee, T.; Yang, L.; Centenera, M.; Butler, L.; Tilley, W.; Hsieh, J.; Ahn, J.; Raj, G.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2011Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progressionWang, Q.; Bailey, C.; Ng, C.; Tiffen, J.; Thoeng, A.; Minhas, V.; Lehman, M.; Hendy, S.; Buchanan, G.; Nelson, C.; Rasko, J.
2011GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cellsChiam, K.; Centenera, M.; Butler, L.; Tilley, W.; Bianco-Miotto, T.; Agoulnik, I.
2015Cabozantinib inhibits abiraterone's upregulation of IGFIR phosphorylation and enhances its anti-prostate cancer activityWang, X.; Huang, Y.; Christie, A.; Bowden, M.; Lee, G.; Kantoff, P.; Sweeney, C.

Discover